Quarterly ResultApr 30, 2026, 05:23 PM
FBLG Q1 Net Loss $(5.0)M; Cash $1.5M; 1-for-20 Reverse Split
AI Summary
FibroBiologics reported a net loss of $(5.0) million for Q1 2026, a slight increase from $(4.97) million in Q1 2025. The company's cash and cash equivalents significantly decreased to $1.5 million as of March 31, 2026, from $4.9 million at year-end 2025, raising substantial doubt about its ability to continue as a going concern. A 1-for-20 reverse stock split was effected on March 30, 2026. The company also formed a wholly-owned subsidiary in Australia in June 2025 to support a Phase 1/2 clinical trial for diabetic foot ulcers.
Key Highlights
- Effected a 1-for-20 reverse stock split on March 30, 2026.
- Reported Q1 2026 net loss of $(5.0) million, compared to $(4.97) million in Q1 2025.
- Cash and cash equivalents decreased 69.7% to $1.5 million as of March 31, 2026.
- Accumulated deficit reached $(59.2) million as of March 31, 2026.
- Research and development expenses rose 65.9% to $2.95 million in Q1 2026.
- Net cash used in operating activities was $(4.36) million in Q1 2026.
- Raised $706 thousand from common stock issuance in Q1 2026.